Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-24T23:06:02.375Z Has data issue: false hasContentIssue false

Topical Mupirocin for Eradication of MRSA Colonization With Mupirocin-Resistant Strains

Published online by Cambridge University Press:  02 January 2015

Makeda Semret
Affiliation:
Infection Prevention and Control Unit and Department of Microbiology, SMBD-Jewish General Hospital, Montreal, Quebec, Canada
Mark A. Miller*
Affiliation:
Infection Prevention and Control Unit and Department of Microbiology, SMBD-Jewish General Hospital, Montreal, Quebec, Canada
*
Department of Microbiology, SMBD-Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec H3T1E2, Canada

Abstract

Topical mupirocin was able to interrupt colonization of 52% and 68% of methicillin-resistant Staphylococcus aureus (MRSA)-colonized patients carrying mupirocin-resistant and -sensitive strains, respectively, including 44.4% and 85.7% of those colonized only in the nares. Although a trend to decreased effectiveness was seen for clearing mupirocin-resistant MRSA this agent can decolonize many patients with resistant strains.

Type
Concise Communications
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bertino, JS Jr. Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. Am J Health-Syst Pharm 1997;54:21852191.CrossRefGoogle ScholarPubMed
2.Miller, MA, Dascal, A, Portnoy, J, Mendelson, J. Development of mupirocin resistance among methiciHin resistant S aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996;17:811813.CrossRefGoogle ScholarPubMed
3.Casewell, MW, Hill, RLR. Mupirocin (‘Pseudomonic add’): a promising new topical antimicrobial agent. J Antimicrob Chemother 1987;19:15.CrossRefGoogle Scholar
4.Fuchs, PC, Jones, RN, Barry, AL. Interpretative criteria for disk-diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol 1990;28:608609.CrossRefGoogle ScholarPubMed
5.Irish, D, Eltringham, I, Teall, A, Pickett, H, Farelly, H, Reith, S, et al. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J Hosp Infect 1998;39:1926.CrossRefGoogle ScholarPubMed
6.Smith, MD, Sanghrajka, M, Lock, S. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;ii:14721473.Google Scholar
7.Bradley, SF, Ramsey, MA, Morton, TM, Kauffman, CA. Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 1995;354358.CrossRefGoogle ScholarPubMed
8.Scully, BE, Briones, F, Gu, JW, Neu, HC. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med 1992;152:353356.CrossRefGoogle ScholarPubMed
9.Kauffman, CA, Terpenning, MS, He, X, Zarins, LT, Ramsey, MA, Jorgensen, KA, et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long term facility with the use of mupirocin ointment. Am J Med 1993;94:371378.CrossRefGoogle ScholarPubMed
10.Harbarth, S, Dharan, S, Liassine, N, Herrault, P, Auckenthaler, R, Pittet, D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:14121416.CrossRefGoogle ScholarPubMed
11.Casewell, MW, Hill, RLR. Elimination of nasal carriage of Staphylococcus aureus with mupirocin (‘Pseudomonic acid’): a controlled trial. J Antimicrob Chemother 1986;17:365372.CrossRefGoogle ScholarPubMed
12.Doebbeling, BN, Breneman, DL, Neu, HC, Aly, R, Yangco, BG, Holley, HP Jr, et al. Elimination of Staphylococcus aureus nasal carriage in healthcare workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis 1993;17:466474.CrossRefGoogle ScholarPubMed